Free Trial

TScan Therapeutics (TCRX) Competitors

TScan Therapeutics logo
$2.29 +0.05 (+2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.34 +0.05 (+2.18%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TCRX vs. MBX, OCGN, ADCT, FULC, INBX, ATXS, CYRX, SLDB, ALMS, and DRUG

Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include MBX Biosciences (MBX), Ocugen (OCGN), ADC Therapeutics (ADCT), Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

TScan Therapeutics vs. Its Competitors

MBX Biosciences (NASDAQ:MBX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, MBX Biosciences had 9 more articles in the media than TScan Therapeutics. MarketBeat recorded 11 mentions for MBX Biosciences and 2 mentions for TScan Therapeutics. MBX Biosciences' average media sentiment score of 1.41 beat TScan Therapeutics' score of 0.32 indicating that MBX Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
6 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TScan Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MBX Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. MBX Biosciences' return on equity of -31.33% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -31.33% -29.96%
TScan Therapeutics -1,964.88%-63.33%-40.19%

MBX Biosciences currently has a consensus price target of $44.00, indicating a potential upside of 172.78%. TScan Therapeutics has a consensus price target of $7.80, indicating a potential upside of 240.61%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than MBX Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
TScan Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

82.8% of TScan Therapeutics shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 4.4% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MBX Biosciences has higher earnings, but lower revenue than TScan Therapeutics. MBX Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$61.92M-$4.54-3.55
TScan Therapeutics$6.96M18.67-$127.50M-$1.09-2.10

Summary

MBX Biosciences beats TScan Therapeutics on 9 of the 14 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRX vs. The Competition

MetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$127.12M$3.44B$6.19B$10.60B
Dividend YieldN/A2.26%5.72%4.86%
P/E Ratio-2.1023.2429.6428.46
Price / Sales18.67477.59577.46128.87
Price / CashN/A44.5736.5560.64
Price / Book0.5410.3512.076.53
Net Income-$127.50M-$52.53M$3.32B$276.75M
7 Day Performance-7.66%-0.22%-0.16%0.20%
1 Month Performance27.22%10.89%5.76%1.67%
1 Year Performance-55.01%14.19%65.71%32.73%

TScan Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRX
TScan Therapeutics
2.8269 of 5 stars
$2.29
+2.2%
$7.80
+240.6%
-57.3%$127.12M$6.96M-2.10100Gap Up
MBX
MBX Biosciences
3.6339 of 5 stars
$14.50
-2.7%
$42.80
+195.2%
N/A$500.89MN/A-3.19N/AInsider Trade
OCGN
Ocugen
1.5417 of 5 stars
$1.60
-6.4%
$6.00
+275.0%
+62.4%$499.84M$4.05M-8.0080News Coverage
ADCT
ADC Therapeutics
2.5356 of 5 stars
$4.63
+4.6%
$7.75
+67.6%
+27.6%$497.25M$70.84M-2.95310Analyst Revision
FULC
Fulcrum Therapeutics
2.7418 of 5 stars
$8.75
-2.7%
$9.60
+9.7%
+166.7%$486.28M$80M-7.17100News Coverage
Analyst Forecast
Analyst Revision
INBX
Inhibrx Biosciences
1.6756 of 5 stars
$34.38
+5.9%
N/A+99.5%$470.27M$200K-3.25166News Coverage
Gap Up
Trading Halted
ATXS
Astria Therapeutics
1.922 of 5 stars
$8.47
+1.9%
$29.50
+248.3%
+3.9%$468.97MN/A-4.2130
CYRX
CryoPort
2.9917 of 5 stars
$9.40
+1.1%
$12.56
+33.6%
+39.3%$465.62M$228.38M7.071,186
SLDB
Solid Biosciences
2.8332 of 5 stars
$6.01
+0.8%
$15.00
+149.6%
-1.1%$464.10M$8.09M-2.15100
ALMS
Alumis
3.4983 of 5 stars
$4.61
+3.8%
$20.17
+337.5%
-65.4%$462.05MN/A0.00N/APositive News
DRUG
Bright Minds Biosciences
3.0991 of 5 stars
$64.97
+2.7%
$81.00
+24.7%
+31.8%$445.81MN/A-69.86N/APositive News

Related Companies and Tools


This page (NASDAQ:TCRX) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners